3,3-dimethyl-N-(2-morpholin-4-ylethyl)butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3,3-dimethyl-N-(2-morpholin-4-ylethyl)butanamide
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.33
• InChiKey: FDJRQJAPQHMCDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pyrrole derivatives as PLK1 inhibitors
  申请人：SENTINEL ONCOLOGY LIMITED

  公开号：US11208405B2

  公开（公告）日：2021-12-28

  The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and R7 is selected from R4. The compounds are useful in the treatment of cancers.

  本发明提供了式 (3) 的化合物： 或其药学上可接受的盐或同系物，其中 Z 是一个 5 元杂芳基环，含有一个或两个氮环成员，可选地还含有一个选自 N 和 O 的杂原子环成员； 环 X 是苯环或吡啶环； 环 Y 是苯、吡啶、噻吩或呋喃环； Ar1 是任选取代的苯、吡啶、噻吩或呋喃环； m 为 0、1 或 2； n 为 0、1 或 2； R1 选自各种取代基： R2 选自氢和 C1-4 烃基； R3 选自氢和 C1-4 烃基； R4 选自各种取代基； R5 选自各种取代基； Ar2 是任选取代的苯基、吡啶基或吡啶酮基团； R6 是 Q1-Ra-Rb 基团； Q1 不存在或为 C1-3 饱和烃连接体； Ra 选自 O、C(O)、C(O)O、CONRc、N(Rc)CO、N(Rc)CONRc、NRc 和 SO2NRc； Rb 选自氢和各种取代基； R7 选自 R4。 这些化合物可用于治疗癌症。
• PYRROLE DERIVATIVES AS PLK1 INHIBITORS
  申请人：SENTINEL ONCOLOGY LIMITED

  公开号：US20200247796A1

  公开（公告）日：2020-08-06

  The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar 1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R 1 is selected from various substituents: R 2 is selected from hydrogen and a C 1-4 hydrocarbon group; R 3 is selected from hydrogen and a C 1-4 hydrocarbon group; R 4 is selected from various substituents; R 5 is selected from various substituents; Ar 2 is an optionally substituted phenyl, pyridyl or pyridone group; R 6 is a group Q 1 -R a —R b ; Q 1 is absent or is a C 1-3 saturated hydrocarbon linker; R a is selected from O; C(O); C(O)O; CONR c ; N(R c )CO; N(R c )CONR c , NR c ; and SO 2 NR c ; R b is selected from hydrogen and various substituents; and R 7 is selected from R 4 . The compounds are useful in the treatment of cancers.